JMP Securities Reiterates Market Outperform on Viridian Therapeutics, Maintains $44 Price Target
Portfolio Pulse from richadhand@benzinga.com
JMP Securities analyst Jason Butler has reiterated a Market Outperform rating on Viridian Therapeutics (NASDAQ:VRDN) and maintained a $44 price target.
July 11, 2023 | 11:52 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
JMP Securities has reiterated a Market Outperform rating on Viridian Therapeutics and maintained a $44 price target.
The reiteration of a Market Outperform rating and a maintained price target by JMP Securities indicates a positive outlook for Viridian Therapeutics. This could potentially lead to an increase in investor confidence and a positive impact on the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100